靶向刺突蛋白受体结合域的促血栓抗体在重症COVID-19中的作用
研究纳入130例住院COVID-19患者,诊断后3.6天采集样本,80%检出识别肝素与血小板因子4复合物(PF4/H)的IgG抗体,41%检出可诱导PF4依赖性P-选择素表达的抗体。PF4/H反应性IgG与靶向SARS-CoV-2刺突蛋白受体结合域(RBD)的抗体相关,RBD特异性抗体与HIT致病抗体存在功能与结构相似性,提示其可能参与COVID-19血栓形成。
要点
- 130例住院COVID-19患者中80%检出PF4/H反应性IgG,41%检出血小板活化抗体。
- PF4/H反应性IgG与靶向SARS-CoV-2刺突蛋白RBD的抗体相关。
- RBD特异性抗体与HIT致病抗体在功能和结构上相似,可能参与COVID-19血栓形成。
核心结论
- COVID-19患者中某些RBD特异性抗体与HIT致病抗体存在功能和结构相似性,提示RBD特异性抗体可能通过新机制促进COVID-19血栓形成。
研究设计与样本
- 研究分析了130例住院COVID-19患者的样本,样本于COVID-19诊断后3.6天采集。
主要发现
- 130例住院患者中80%具有识别肝素与血小板因子4复合物(PF4/H)的IgG抗体,41%具有在CpG寡脱氧核苷酸处理的正常血小板中诱导PF4依赖性P-选择素表达的抗体。
- 与HIT不同,无论近期有无肝素暴露,COVID-19患者中均可发现PF4/H反应性和血小板活化抗体。
- PF4/H反应性IgG抗体与靶向SARS-CoV-2刺突蛋白受体结合域(RBD)的抗体相关。
- 向COVID-19血浆或纯化IgG中加入外源性RBD或去除RBD反应性IgG,可显著降低其激活血小板的能力。
- 从COVID-19患者外周血B细胞中克隆出能激活血小板的RBD特异性抗体,其重链互补决定区3(HCDR3)序列基序与致病性HIT抗体相似,且具有这些HCDR3特征的IgG+ B细胞在重症COVID-19患者中显著扩增。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thromboembolic complication is common in severe coronavirus disease 2019 (COVID-19), leading to an investigation into the presence of prothrombotic antibodies akin to those found in heparin-induced thrombocytopenia (HIT). In a study of samples from 130 hospitalized patients, collected 3.6 days after COVID-19 diagnosis, 80% had immunoglobulin G (IgG) antibodies recognizing complexes of heparin and platelet factor 4 (PF4; PF4/H), and 41% had antibodies inducing PF4-dependent P-selectin expression in CpG oligodeoxynucleotide-treated normal platelets. Unlike HIT, both PF4/H-reactive and platelet-activating antibodies were found in patients with COVID-19 regardless of recent heparin exposure. Notably, PF4/H-reactive IgG antibodies correlated with those targeting the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 spike protein. Moreover, introducing exogenous RBD to or removing RBD-reactive IgG from COVID-19 plasma or IgG purified from COVID-19 plasma significantly reduced their ability to activate platelets. RBD-specific antibodies capable of platelet activation were cloned from peripheral blood B cells of patients with COVID-19. These antibodies possessed sequence motifs in the heavy-chain complementarity-determining region 3 (HCDR3), resembling those identified in pathogenic HIT antibodies. Furthermore, IgG+ B cells having these HCDR3 signatures were markedly expanded in patients with severe COVID-19. Importantly, platelet-activating antibodies present in patients with COVID-19 were associated with a specific elevation of platelet α-granule proteins in the plasma and showed a positive correlation with markers for inflammation and tissue damage, suggesting a functionality of these antibodies in patients. The demonstration of functional and structural similarities between certain RBD-specific antibodies in patients with COVID-19 and pathogenic antibodies typical of HIT suggests a novel mechanism by which RBD-specific antibodies might contribute to thrombosis in COVID-19.
引用
- Zhu W, Zheng Y, Yu M, et al. Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19. Blood. 2025. PMID: 39576992. doi:10.1182/blood.2024025010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。